Gynaecological cancer
Explore our latest news, features and educational resources in this specialist area.
SMC accepts treatment for gynaecological cancers
Olaparib is accepted for restricted use within NHS Scotland.
SMC accepts niraparib for some gynecological cancers
Research showed that niraparib significantly improved progression-free survival compared with placebo.
Ovarian cancer treatment recommended via Cancer Drugs Fund
NICE draft guidance recommends olaparib in combination with bevacizumab for some people with advanced, high-grade epithelial ovarian, fallopian tube or primary peritoneal cancer.
Niraparib (Zejula▼): reports of severe hypertension and posterior reversible encephalopathy syndrome (PRES), particularly in early treatment
Monitor blood pressure at least weekly for 2 months from initiation and then monthly afterwards for the first year and periodically thereafter during treatment
